Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Enrollment for PII of Erbitux for SCCHN in Japan Completed: Merck
July 5, 2010
- Alexion to Raise People's Awareness of PNH in Japan: CEO Bell
July 5, 2010
- Chuikyo Members Representing Hospital Associations Criticized by Their Colleagues
July 5, 2010
- MK-4305 Improves Sleep Efficiency in PIIb: US Merck
July 5, 2010
- DSP to Enhance Its MR Support System
July 5, 2010
- Daiichi Sankyo to Develop Vaccine Business in Japan and Emerging Markets
June 28, 2010
- Otsuka Gives Apple's iPad to Every MR
June 28, 2010
- Zometa Improves OS in Patients with De Novo Multiple Myeloma
June 28, 2010
- Bayer to Strengthen Marketing Structure in General Medicine
June 28, 2010
- Research-Driven Companies Also to Be Blamed for Jam of Generics: Mr Sawai
June 28, 2010
- Pfizer's Crizotinib to Contribute to Personalized Treatment of NSCLC
June 28, 2010
- MTPC Presents Business Improvement Plans to Korosho
June 28, 2010
- Ethical Drugs' Sales Up 10.2% in April: Crecon
June 28, 2010
- Sprycel Effective in First-Line Therapy for CML-CP
June 28, 2010
- Ensure Value-Matched Sales of Drugs: New JPMA Marketing Committee Chairman
June 28, 2010
- FPMAJ Subcommittee Calls For Full-Scale Introduction of Premium for Development of New Drugs
June 28, 2010
- 4-Year Follow-up Data from Sprycel-Treated Patients Announced
June 28, 2010
- Kowa Licenses Livalo to Abbott in Australia, New Zealand
June 28, 2010
- 2 Sets of GLs for Development of Vaccines Issued
June 28, 2010
- Meiji Seika Begins PIIa Study for Fibromyalgia with Mirtazapine
June 28, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…